Overview

* Spruce Biosciences ( SPRB ) reports Q3 net loss of $8.2 mln, with reduced operating expenses

* Company secured $50 mln in private placement financing from healthcare investors

Outlook

* Company expects funding to last into Q4 2026

Result Drivers

* PRIVATE PLACEMENT - Co completed $50 mln private placement financing to support TA-ERT development

* R&D EXPENSES - Decrease in R&D expenses due to cessation of tildacerfont development, focus shifted to TA-ERT

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$8.21

Income mln

Q3 -$8.23

Income mln

From

Operatio

ns

Q3 $8.23

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* Wall Street's median 12-month price target for Spruce Biosciences Inc ( SPRB ) is $132.00, about 3.8% above its November 7 closing price of $127.00

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)